Acquires exclusive rights to

获取独占权利

manufacture, market and distribute Rivotril in India

在印度制造、销售和分销Rivotril

Adds a

添加一个

clonazepam Textbook brand with strong clinical legacy and specialist recall

具有强大临床传承和专家认可的氯硝西泮教科书品牌

Strengthens Mankind Pharma’s

加强人类制药公司的

strategic focus on chronic and CNS therapies

专注于慢性病和中枢神经系统治疗的战略重点

Creates a platform for

创建一个平台用于

future expansion through potential line extensions

通过潜在的线路扩展实现未来扩展

Mankind Pharma Limited today announced that it has acquired the brand Rivotril from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country. Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions.

今日，Mankind Pharma Limited宣布已从罗氏收购了Rivotril品牌在印度市场的权益，并获得该产品在全国范围内制造、营销和分销的独家权利。Rivotril是氯硝西泮的创新/参考品牌，广泛用于神经和精神疾病的治疗。

Often regarded as a Textbook brand in its category with a strong clinical legacy, Rivotril further strengthens Mankind Pharma’s presence in the central nervous system (CNS) therapy segment and complements its existing neuro portfolio..

通常被视为其类别中的教科书品牌，并拥有强大的临床传承，Rivotril进一步增强了人类制药公司在中枢神经系统（CNS）治疗领域的地位，并补充了其现有的神经科产品组合。

The acquisition builds on Mankind Pharma’s growing focus on chronic therapies, where the company has steadily expanded its presence through new launches, in-licensing partnerships and portfolio additions across key therapeutic areas. Chronic therapies now account for a rising share of the company’s overall business as they continue to scale specialty segments and deepen engagement with specialists and key opinion leaders.

此次收购建立在人类制药公司对慢性病治疗日益增长的关注之上，该公司通过新产品发布、许可合作以及在关键治疗领域的产品组合扩充，稳步扩大了其影响力。随着公司在专业领域不断扩大规模，并加深与专家及关键意见领袖的互动，慢性病治疗目前在公司的整体业务中占据了越来越大的份额。

Furthermore, the addition of Rivotril, an innovator brand with great recall amongst specialists, will strengthen its CNS portfolio and expand treatment options for patients managing neurological conditions..

此外，添加具有很高专业知名度的创新品牌Rivotril将加强其中枢神经系统产品组合，并扩展管理神经疾病的患者的治疗选择。

Atish Majumdar, Senior President, Sales & Marketing, Mankind Pharma Specialty Business, said:

阿蒂什·马宗达尔，高级总裁，销售与营销，人类制药专业业务部，表示：

This acquisition is aligned with our strategic focus on strengthening our presence in

此次收购符合我们加强在该领域存在的战略重点

chronic therapies and specialty therapies.

慢性病治疗和专科治疗。

Going forward, we see strong opportunities to build on this platform

展望未来，我们看到在此平台基础上建立强大的机会。

through potential line extensions,

通过潜在的线路扩展，

addressing the evolving needs of patients and physicians in the CNS therapy area. Leveraging our large field force and nationwide distribution network, we are well positioned to build the brand and support physicians in delivering better outcomes for patients across India.”

满足中枢神经系统治疗领域中患者和医生不断变化的需求。利用我们庞大的现场团队和全国分销网络，我们有能力在印度各地建立品牌并支持医生为患者提供更好的治疗效果。

Mankind Pharma will leverage its nationwide distribution network and large field force to support wider access to Rivotril across healthcare institutions and prescribers in India. The company currently engages with over 5 lakh doctors and has built a strong prescription share in the Indian pharmaceutical market, enabling deep penetration across urban and semi-urban markets..

曼克药业将利用其遍布全国的分销网络和庞大的现场团队，支持印度各地医疗机构和处方医生更广泛地获取Rivotril。该公司目前与超过50万名医生保持联系，并在印度制药市场建立了强大的处方份额，实现了在城市和半城市市场的深度渗透。